Silo pharma's alzheimer's candidate spc-14 featured in leading scientific peer-reviewed journal

Manuscript featured in leading open-access scientific journal alzheimer's research & therapy sarasota, fl, aug. 21, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its alzheimer's disease (ad) therapeutic, spc-14, in alzheimer's research & therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into ad. the study, titled “combinatorial targeting of nmdars and 5-ht4rs exerts beneficial effects in a mouse model of alzheimer's disease,” details research methods and results indicating that the combined administration of (r,s)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in ad.
SILO Ratings Summary
SILO Quant Ranking